Audet & Partners, LLP is investigating claims that may form the basis of a class action lawsuit against Mars Petcare, parent company of Pedigree, the manufacturer of Dentastix dog treats.  For some time, Pedigree has been marketing Dentastix as facilitating “up to 80% tartar reduction” in dogs who chew Dentastix.  The National Advertising Division (NAD) of the Council of Better Business Bureaus, however, has issued a public statement disputing the claimed efficacy of Dentastix.  The NAD has stated that in clinical tests, the actual reduction of tartar buildup in dogs was approximately 47%.

The NAD statement claims that Pedigree essentially misstated the results of  clinical trial undertaken by Summit Ridge Farms, the results of which had suggested a mean reduction in tartar buildup of 46.7% over a 28-day trial.  The NAD claims that Pedigree then undertook a post-hoc analysis of the Summit Ridge study results and reclassified the test subjects in a way that allegedly overstated the effectiveness of Dentastix chews in reducing tartar buildup.

The claims set forth in the opinion recently issued by the NAD may give rise to a Dentastix class action lawsuit on behalf of purchasers of Dentastix for false advertising and other causes of action.  If you have purchased Dentastix and given the product to your dog, you are urged to contact us for a free, confidential case evaluation.  You can call us at (800) 965-1461, complete and submit our online case inquiry form on the right side of this page, or e-mail class action attorney Michael McShane at mmcshane@audetlaw.com.